Health
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
PRINCETON, N.J., July 21, 2025--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review...
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/0e283b54e6984d99490734543b137066"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L7biSRwZ.YoMHYim0qGLsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0e283b54e6984d99490734543b137066","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.MaDo1JqTOTfXiUqv.ziqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0e283b54e6984d99490734543b137066","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Applications supported by positive results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials, in which significantly more patients treated with Sotyktu achieved ACR20 response compared with placebo at Week 16","length":229,"tagName":"p","attribs":{}},{"type":"text","content":"U.S. Food and Drug Administration assigned a target action date of March 6, 2026","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., July 21, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026. This latest regulatory milestone is in addition to the sNDA acceptances by China’s Center for Drug Evaluation of National Medical Products Administration and Japan's Ministry of Health, Labour and Welfare for Sotyktu for the treatment of adults with active psoriatic arthritis. The European Medicines Agency has also validated Bristol Myers Squibb's Type II variation application to expand the indication for Sotyktu to include this disease.","length":845,"tagName":"p"},{"type":"text","content":""There is a significant need for additional oral treatments for individuals living with psoriatic arthritis, and today’s announcement brings us one step closer to bringing Sotyktu to these patients," said Roland Chen, MD, Senior Vice President, Drug Development, Immuno...